Ost-müük MediciNova - MNOV CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | - | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.030779% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | -0.013666% | ||||||||
Ööpäeva tasu aeg | 22:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | N/A |
Avatud* | N/A |
Aastane muutus* | N/A |
Päeva ulatus* | N/A |
52 nädala ulatus | 1.95-3.18 |
Keskmine maht (10 päeva) | 19.93K |
Keskmine maht (3 kuud) | 1.74M |
Turukapitalisatsioon | 117.71M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 49.05M |
Tulu | N/A |
EPS | -0.27 |
Dividendid (% kasumist) | N/A |
Beeta | 0.97 |
Järgmine tuluaruande kuupäev | Feb 14, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|
MediciNova Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 | 4.0375 |
Kogu tegevuskulu | 10.8818 | 13.0271 | 15.5868 | 14.0311 | 14.1783 | 14.2533 |
Müük/Üldine/admin kulud, kokku | 7.36266 | 8.80335 | 9.96101 | 7.95204 | 6.69349 | 5.71529 |
Uuringud ja arendus | 3.51917 | 4.22375 | 5.62581 | 6.07904 | 7.48484 | 8.53803 |
Tulud majandustegevusest | -10.8818 | -13.0271 | -15.5868 | -14.0311 | -14.1783 | -10.2158 |
Intressitulud (kulu), muud tulud, neto | 0.0662 | 0.14521 | 0.93991 | 1.14824 | 0.36118 | 0.14363 |
Muud, neto | -0.04658 | -0.0253 | -0.02289 | -0.04616 | -0.0384 | -0.0595 |
Netotulu enne makse | -10.8622 | -12.9072 | -14.6698 | -12.929 | -13.8555 | -10.1317 |
Netotulu pärast makse | -10.866 | -11.8631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
Netotulu enne erikulusid | -10.866 | -11.8631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
Netotulu | -10.866 | -11.1631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
Arvestatav tulu, v a erikulud | -10.866 | -11.8631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
Arvestatav tulu, koos erikuludega | -10.866 | -11.1631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
Jaotamisele kuuluv netotulu | -10.866 | -11.1631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
Keskmine jaotamisele kuuluv aktsia kohta | 32.9867 | 35.137 | 41.1249 | 43.1588 | 44.4134 | 48.5963 |
Jaotatav EPS, v a erakorralised kulud | -0.3294 | -0.33762 | -0.35684 | -0.29986 | -0.31193 | -0.20854 |
Jaotamisele kuuluv normaal-EPS | -0.3294 | -0.33762 | -0.35684 | -0.29986 | -0.31193 | -0.20854 |
Erakorralised kulud kokku | 0.7 | 0 | ||||
Tulu | 4.0375 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Kogutulu | 4 | 0 | 0.0375 | 0 | 0 |
Tulu | 4 | 0 | 0.0375 | 0 | 0 |
Kogu tegevuskulu | 4.20153 | 4.30951 | 3.63944 | 2.10283 | 3.41001 |
Müük/Üldine/admin kulud, kokku | 2.05626 | 1.78239 | 1.55082 | 0.32582 | 1.29802 |
Uuringud ja arendus | 2.14527 | 2.52712 | 2.08862 | 1.77701 | 2.112 |
Tulud majandustegevusest | -0.20153 | -4.30951 | -3.60194 | -2.10283 | -3.41001 |
Intressitulud (kulu), muud tulud, neto | 0.03667 | 0.03434 | 0.03615 | 0.03647 | 0.03734 |
Muud, neto | -0.02294 | -0.00897 | -0.01338 | -0.01421 | -0.01374 |
Netotulu enne makse | -0.1878 | -4.28414 | -3.57917 | -2.08058 | -3.38642 |
Netotulu pärast makse | -0.1878 | -4.28414 | -3.57917 | -2.08315 | -3.38642 |
Netotulu enne erikulusid | -0.1878 | -4.28414 | -3.57917 | -2.08315 | -3.38642 |
Netotulu | -0.1878 | -4.28414 | -3.57917 | -2.08315 | -3.38642 |
Arvestatav tulu, v a erikulud | -0.1878 | -4.28414 | -3.57917 | -2.08315 | -3.38642 |
Arvestatav tulu, koos erikuludega | -0.1878 | -4.28414 | -3.57917 | -2.08315 | -3.38642 |
Jaotamisele kuuluv netotulu | -0.1878 | -4.28414 | -3.57917 | -2.08315 | -3.38642 |
Keskmine jaotamisele kuuluv aktsia kohta | 47.5353 | 48.7984 | 48.9878 | 49.0475 | 49.0433 |
Jaotatav EPS, v a erakorralised kulud | -0.00395 | -0.08779 | -0.07306 | -0.04247 | -0.06905 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.00395 | -0.08779 | -0.07306 | -0.04247 | -0.06905 |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Käibevarad kokku | 24.7038 | 28.3283 | 62.7584 | 64.3046 | 60.7169 | 72.0089 |
Raha ja lühiajalised investeeringud | 24.118 | 27.9917 | 62.3134 | 63.7927 | 60.0368 | 71.4309 |
Raha ja ekvivalendid | 24.118 | 27.9917 | 62.3134 | 63.7927 | 60.0368 | 71.4309 |
Prepaid Expenses | 0.58581 | 0.33658 | 0.44494 | 0.51192 | 0.68017 | 0.57799 |
Total Assets | 39.8131 | 43.4191 | 77.2227 | 79.2052 | 75.4191 | 87.4065 |
Property/Plant/Equipment, Total - Net | 0.09072 | 0.06289 | 0.05313 | 0.44055 | 0.0557 | 0.88178 |
Goodwill, Net | 9.60024 | 9.60024 | 9.60024 | 9.60024 | 9.60024 | 9.60024 |
Intangibles, Net | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 |
Long Term Investments | 0.61833 | 0.61666 | 0 | |||
Total Current Liabilities | 1.63104 | 2.88097 | 2.19191 | 2.22824 | 2.19395 | 2.83291 |
Accounts Payable | 0.36728 | 1.52023 | 0.61675 | 0.45133 | 0.61663 | 0.40274 |
Accrued Expenses | 1.26377 | 1.36074 | 1.57516 | 1.77691 | 1.57732 | 2.43017 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5.28121 | 4.77692 | 4.11508 | 4.31055 | 4.09261 | 3.72937 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Income Tax | 1.956 | 0.20179 | 0.20179 | 0.20179 | 0.20179 | 0.20179 |
Other Liabilities, Total | 1.69416 | 1.69416 | 1.72137 | 1.88052 | 1.69687 | 0.69467 |
Total Equity | 34.5319 | 38.6421 | 73.1076 | 74.8946 | 71.3265 | 83.6771 |
Common Stock | 0.03453 | 0.03645 | 0.04208 | 0.04391 | 0.04503 | 0.04904 |
Additional Paid-In Capital | 364.886 | 380.157 | 429.29 | 444.016 | 454.297 | 476.788 |
Retained Earnings (Accumulated Deficit) | -330.293 | -341.456 | -356.131 | -369.073 | -382.927 | -393.061 |
Other Equity, Total | -0.096 | -0.09462 | -0.09315 | -0.09268 | -0.08822 | -0.09888 |
Total Liabilities & Shareholders’ Equity | 39.8131 | 43.4191 | 77.2227 | 79.2052 | 75.4191 | 87.4065 |
Total Common Shares Outstanding | 34.5237 | 36.4529 | 42.0813 | 43.9081 | 45.0246 | 49.0433 |
Property/Plant/Equipment, Total - Gross | 0.5346 | 0.53666 | 0.93841 | 0.57932 | 1.30698 | |
Accumulated Depreciation, Total | -0.47172 | -0.48353 | -0.49786 | -0.52362 | -0.4252 | |
Other Long Term Assets, Total | 0.01096 | 0.01096 | 0.05981 | 0.24624 | 0.11549 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 81.4681 | 78.9097 | 76.1601 | 72.0089 | 68.8311 |
Raha ja lühiajalised investeeringud | 76.3018 | 77.7923 | 75.0254 | 71.4309 | 67.6953 |
Raha ja ekvivalendid | 76.3018 | 77.7923 | 75.0254 | 71.4309 | 67.6953 |
Laekumata arved, neto | 4 | ||||
Accounts Receivable - Trade, Net | 4 | ||||
Prepaid Expenses | 1.16628 | 1.11744 | 1.13473 | 0.57799 | 1.1359 |
Total Assets | 96.1007 | 93.6839 | 91.624 | 87.4065 | 84.1752 |
Property/Plant/Equipment, Total - Net | 0.04893 | 0.06857 | 0.94607 | 0.88178 | 0.83204 |
Goodwill, Net | 9.60024 | 9.60024 | 9.60024 | 9.60024 | 9.60024 |
Intangibles, Net | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 |
Other Long Term Assets, Total | 0.18343 | 0.30533 | 0.11754 | 0.11549 | 0.11176 |
Total Current Liabilities | 1.8311 | 2.46657 | 4.20211 | 2.83291 | 2.97624 |
Accounts Payable | 0.42815 | 0.60716 | 0.64242 | 0.40274 | 0.66525 |
Accrued Expenses | 1.40295 | 1.85942 | 1.86553 | 2.43017 | 2.31099 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3.72927 | 4.44953 | 5.14162 | 3.72937 | 3.8109 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Income Tax | 0.20179 | 0.20179 | 0.20179 | 0.20179 | 0.20179 |
Other Liabilities, Total | 1.69637 | 1.78117 | 0.73772 | 0.69467 | 0.63287 |
Total Equity | 92.3715 | 89.2343 | 86.4823 | 83.6771 | 80.3643 |
Common Stock | 0.04877 | 0.04892 | 0.04903 | 0.04904 | 0.04904 |
Additional Paid-In Capital | 475.532 | 476.678 | 477.506 | 476.788 | 476.869 |
Retained Earnings (Accumulated Deficit) | -383.115 | -387.399 | -390.978 | -393.061 | -396.448 |
Other Equity, Total | -0.09504 | -0.09368 | -0.09504 | -0.09888 | -0.10631 |
Total Liabilities & Shareholders’ Equity | 96.1007 | 93.6839 | 91.624 | 87.4065 | 84.1752 |
Total Common Shares Outstanding | 48.7685 | 48.9242 | 49.0283 | 49.0433 | 49.0433 |
Other Current Liabilities, Total | 1.69416 |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netotulu/algväärtus | -10.866 | -11.1631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
Raha majandustegevusest | -6.54621 | -6.92393 | -9.11412 | -9.12499 | -10.8264 | -9.38161 |
Raha majandustegevusest | 0.01413 | 0.0281 | 0.02588 | 0.02394 | 0.02134 | 0.02615 |
Mittelikviidsed varad | 4.00277 | 4.47662 | 6.31044 | 4.11265 | 3.17555 | 1.93444 |
Cash Taxes Paid | 0.00604 | 0.0092 | 0.00601 | 0.01127 | 0.00149 | 0 |
Muutused tööjõus | 0.30287 | 1.48869 | -0.77535 | -0.31992 | -0.16936 | -1.20794 |
Tulu investeeringutelt | -0.08448 | 0 | 0.62632 | -0.01127 | -0.03649 | -0.02873 |
Kapitalikulutused | -0.08448 | 0 | -0.0102 | -0.01127 | -0.03649 | -0.02873 |
Rahavood investeeringutelt | 8.66564 | 10.797 | 42.8088 | 10.6156 | 7.10576 | 20.778 |
Aktsiate emiteerimine (tagasiost), neto | 8.66564 | 10.797 | 42.8088 | 10.6156 | 7.3096 | 20.8964 |
Muutused valuutakursside kõikumisest | 0.00635 | 0.00061 | 0.00069 | -0.00005 | 0.0012 | 0.02655 |
Rahaline kogumuutus | 2.04129 | 3.87371 | 34.3217 | 1.47924 | -3.75589 | 11.3942 |
Deferred Taxes | -1.75421 | 0 | 0 | |||
Muud rahavood investeeringutelt, kokku | 0.63652 | 0 | ||||
Rahavoogudesse investeerimine | -0.20384 | -0.11837 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -0.1878 | -4.47194 | -8.05111 | -10.1342 | -3.38642 |
Cash From Operating Activities | -3.85395 | -2.72702 | -5.74264 | -9.38161 | -3.7284 |
Cash From Operating Activities | 0.00645 | 0.01261 | 0.01978 | 0.02615 | 0.00443 |
Non-Cash Items | 1.13964 | 1.89554 | 2.63777 | 1.93444 | 0.12623 |
Changes in Working Capital | -4.81224 | -0.16322 | -0.34907 | -1.20794 | -0.47264 |
Cash From Investing Activities | 0 | -0.02579 | -0.02873 | -0.02873 | |
Capital Expenditures | 0 | -0.02579 | -0.02873 | -0.02873 | |
Cash From Financing Activities | 20.0999 | 20.4897 | 20.7393 | 20.778 | 0 |
Financing Cash Flow Items | -0.11835 | -0.11837 | -0.11837 | -0.11837 | 0 |
Issuance (Retirement) of Stock, Net | 20.2183 | 20.608 | 20.8577 | 20.8964 | 0 |
Foreign Exchange Effects | 0.0191 | 0.01864 | 0.02071 | 0.02655 | -0.0073 |
Net Change in Cash | 16.2651 | 17.7555 | 14.9886 | 11.3942 | -3.7357 |
Cash Taxes Paid | 0 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
3D Investment Partners Pte. Ltd | Investment Advisor | 11.2181 | 5502047 | 0 | 2022-07-08 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.7265 | 1827732 | 0 | 2022-09-30 | LOW |
EW Healthcare Partners | Venture Capital | 2.2549 | 1105941 | 0 | 2022-09-30 | LOW |
Iwaki (Yuichi) | Individual Investor | 2.2263 | 1091933 | 0 | 2022-04-18 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.428 | 700379 | -4708 | 2022-09-30 | LOW |
Citi Investment Research (US) | Research Firm | 0.918 | 450222 | 2265 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8826 | 432873 | 2499 | 2022-09-30 | LOW |
Millennium Management LLC | Hedge Fund | 0.7196 | 352956 | -2967 | 2022-09-30 | HIGH |
Matsuda (Kazuko) | Individual Investor | 0.6586 | 322996 | 0 | 2022-04-18 | LOW |
JPMorgan Private Bank (United States) | Bank and Trust | 0.6077 | 298076 | 2700 | 2022-09-30 | LOW |
Bridgeway Capital Management, LLC | Investment Advisor | 0.3979 | 195147 | 0 | 2022-09-30 | LOW |
UBS Financial Services, Inc. | Investment Advisor | 0.3752 | 184028 | 0 | 2022-09-30 | LOW |
Barclays Capital | Research Firm | 0.3228 | 158300 | -22900 | 2022-09-30 | HIGH |
BofA Global Research (US) | Research Firm | 0.3155 | 154751 | -4700 | 2022-09-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.3054 | 149800 | -11300 | 2022-09-30 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2901 | 142298 | 0 | 2022-09-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.2745 | 134656 | 3276 | 2022-09-30 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.2306 | 113113 | -39256 | 2022-09-30 | LOW |
Newton Investment Management North America, LLC | Investment Advisor | 0.1865 | 91480 | 0 | 2022-09-30 | MED |
Capricorn Fund Managers Ltd | Investment Advisor | 0.136 | 66716 | 66716 | 2022-12-31 | HIGH |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com GroupKauplejad
Igakuiste aktiivsete klientide arv
Igakuine investeerimise maht
Igakuiselt välja võetud
Kauplemiskalkulaator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
MediciNova Company profile
Ettevõttest MediciNova
MediciNova, Inc. on biofarmatseutiline ettevõte. Ettevõte keskendub ravimite väljatöötamisele tõsiste haiguste raviks, mille puhul on rahuldamata meditsiinilised vajadused, ning keskendub kaubanduslikult Ameerika Ühendriikide turule. Ettevõte keskendub MN-166 (ibudilast) ja MN-001 (tipelukast) arendamisele. Tema ibudilast on mõeldud neuroloogiliste ja muude haiguste, näiteks progresseeruva hulgiskleroosi (MS), amüotroofilise lateraalskleroosi (ALS), kemoteraapiast tingitud perifeerse neuropaatia, degeneratiivse emakakaela müelopaatia, glioblastoomi, ainete sõltuvuse ja sõltuvuse ning ägeda hingamishäiresündroomi ennetamiseks. Selle tipelukast on mõeldud fibrootiliste haiguste, näiteks mittealkohoolse steatohepatiidi (NASH) ja idiopaatilise kopsufibroosi (IPF) raviks. Ettevõtte tooteprogrammis on ka MN-221 (bedoradriin) astma ägeda ägenemise raviks ja MN-029 (denibuliin) tahkete kasvajate raviks. Ettevõtte ibudilast on väljatöötamisel erinevate neuroloogiliste ja muude haiguste raviks.
Industry: | Bio Therapeutic Drugs |
Suite 650
4275 Executive Square
LA JOLLA
CALIFORNIA 92037
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 485,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com